Plasma Treatment Limits Human Melanoma Spheroid Growth and Metastasis Independent of the Ambient Gas Composition.

MNT-1 ROS SK-MEL-28 kINPen oncology plasma medicine reactive oxygen species

Journal

Cancers
ISSN: 2072-6694
Titre abrégé: Cancers (Basel)
Pays: Switzerland
ID NLM: 101526829

Informations de publication

Date de publication:
09 Sep 2020
Historique:
received: 22 08 2020
revised: 03 09 2020
accepted: 07 09 2020
entrez: 12 9 2020
pubmed: 13 9 2020
medline: 13 9 2020
Statut: epublish

Résumé

Melanoma skin cancer is still a deadly disease despite recent advances in therapy. Previous studies have suggested medical plasma technology as a promising modality for melanoma treatment. However, the efficacy of plasmas operated under different ambient air conditions and the comparison of direct and indirect plasma treatments are mostly unexplored for this tumor entity. Moreover, exactly how plasma treatment affects melanoma metastasis has still not been explained. Using 3D tumor spheroid models and high-content imaging technology, we addressed these questions by utilizing one metastatic and one non-metastatic human melanoma cell line targeted with an argon plasma jet. Plasma treatment was toxic in both cell lines. Modulating the oxygen and nitrogen ambient air composition (100/0, 75/25, 50/50, 25/75, and 0/100) gave similar toxicity and reduced the spheroid growth for all conditions. This was the case for both direct and indirect treatments, with the former showing a treatment time-dependent response while the latter resulted in cytotoxicity with the longest treatment time investigated. Live-cell imaging of in-gel cultured spheroids indicated that plasma treatment did not enhance metastasis, and flow cytometry showed a significant modulation of S100A4 but not in any of the five other metastasis-related markers (β-catenin, E-cadherin, LEF1, SLUG, and ZEB1) investigated.

Identifiants

pubmed: 32917026
pii: cancers12092570
doi: 10.3390/cancers12092570
pmc: PMC7565798
pii:
doi:

Types de publication

Journal Article

Langues

eng

Subventions

Organisme : Bundesministerium für Bildung und Forschung
ID : 03Z22DN11
Organisme : Bundesministerium für Bildung und Forschung
ID : 03Z22Di1
Organisme : European Social Fund
ID : ESF/14-BM-A55-0006-18

Références

Nat Rev Cancer. 2003 May;3(5):380-7
pubmed: 12724736
J Clin Invest. 2009 Jun;119(6):1420-8
pubmed: 19487818
Pigment Cell Melanoma Res. 2012 May;25(3):343-53
pubmed: 22336146
Biomaterials. 2016 Nov;108:197-213
pubmed: 27639438
PLoS One. 2016 Sep 01;11(9):e0160667
pubmed: 27584003
Nat Rev Drug Discov. 2009 Jul;8(7):579-91
pubmed: 19478820
Sci Rep. 2017 Aug 16;7(1):8319
pubmed: 28814809
Expert Rev Anticancer Ther. 2010 Nov;10(11):1811-23
pubmed: 21080806
PLoS One. 2014 Jan 21;9(1):e86173
pubmed: 24465942
Free Radic Res. 2014 May;48(5):542-9
pubmed: 24528134
Anal Chem. 2014 Sep 2;86(17):8842-9
pubmed: 25118958
Biointerphases. 2015 Jun 06;10(2):029518
pubmed: 25947392
AMA Arch Derm Syphilol. 1954 Feb;69(2):133-49
pubmed: 13123538
Environ Mol Mutagen. 2018 May;59(4):268-277
pubmed: 29417643
Br J Cancer. 2001 Nov 2;85(9):1304-10
pubmed: 11720465
Int J Mol Sci. 2017 Apr 19;18(4):
pubmed: 28422070
Trends Biotechnol. 2018 Nov;36(11):1183-1198
pubmed: 30033340
Pigment Cell Melanoma Res. 2011 Jun;24(3):422-9
pubmed: 21410654
Antioxid Redox Signal. 2009 Apr;11(4):777-90
pubmed: 18828708
Cancers (Basel). 2019 Dec 02;11(12):
pubmed: 31810265
Mutat Res Genet Toxicol Environ Mutagen. 2016 Mar;798-799:48-54
pubmed: 26994493
Sci Rep. 2016 Feb 24;6:21464
pubmed: 26908060
Exp Cell Res. 2004 Mar 10;294(1):60-7
pubmed: 14980501
Oncotarget. 2016 Apr 5;7(14):17844-53
pubmed: 26910282
Biointerphases. 2015 Jun 01;10(2):029506
pubmed: 25832438
Biomolecules. 2020 Jul 08;10(7):
pubmed: 32650505
Oxid Med Cell Longev. 2019 Oct 8;2019:9062098
pubmed: 31687089
Redox Biol. 2019 Sep;26:101301
pubmed: 31442912
Pathol Res Pract. 2019 Jan;215(1):21-28
pubmed: 30501931
Biol Chem. 2013 Feb;394(2):239-50
pubmed: 23152406
BMC Cancer. 2016 Jul 07;16:413
pubmed: 27389173
Adv Drug Deliv Rev. 2014 Dec 15;79-80:3-18
pubmed: 24997339
Science. 2015 Apr 3;348(6230):69-74
pubmed: 25838375
Cancers (Basel). 2018 Oct 23;10(11):
pubmed: 30360539
J Vis Exp. 2017 Nov 17;(129):
pubmed: 29286412
Adv Exp Med Biol. 2016;899:167-96
pubmed: 27325267
Phys Biol. 2016 Sep 07;13(5):056001
pubmed: 27603748
Adv Sci (Weinh). 2020 Mar 30;7(10):1903438
pubmed: 32440479
Int J Radiat Oncol Biol Phys. 1990 Nov;19(5):1191-7
pubmed: 2254111
Sci Rep. 2019 Jan 24;9(1):634
pubmed: 30679720
Semin Cutan Med Surg. 1997 Jun;16(2):122-30
pubmed: 9220551
J Biotechnol. 2010 Jul 1;148(1):3-15
pubmed: 20097238
Oncogene. 2006 Jun 22;25(26):3689-98
pubmed: 16462764

Auteurs

Sybille Hasse (S)

ZIK plasmatis, Leibniz Institute for Plasma Science and Technology, Felix-Hausdorff-Str. 2, 17489 Greifswald, Germany.

Tita Meder (T)

ZIK plasmatis, Leibniz Institute for Plasma Science and Technology, Felix-Hausdorff-Str. 2, 17489 Greifswald, Germany.

Eric Freund (E)

ZIK plasmatis, Leibniz Institute for Plasma Science and Technology, Felix-Hausdorff-Str. 2, 17489 Greifswald, Germany.
Department of General, Visceral, Thoracic and Vascular Surgery, Greifswald University Medical Center, Ferdinand-Sauerbruch-Str., 17475 Greifswald, Germany.

Thomas von Woedtke (T)

ZIK plasmatis, Leibniz Institute for Plasma Science and Technology, Felix-Hausdorff-Str. 2, 17489 Greifswald, Germany.
Institute for Hygiene and Environmental Medicine, Greifswald University Medical Center, Walther-Rathenau-Str. 48, 17489 Greifswald, Germany.

Sander Bekeschus (S)

ZIK plasmatis, Leibniz Institute for Plasma Science and Technology, Felix-Hausdorff-Str. 2, 17489 Greifswald, Germany.

Classifications MeSH